WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:     | 1 |   ...   | 3 | 4 || 6 | 7 |   ...   | 9 |

«Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in ...»

-- [ Page 5 ] --

Clinical Worsening and Suicide Risk: Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a dayto-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.

Interference with Cognitive and Motor Performance Clinical studies were performed to examine the effects of venlafaxine on behavioral performance of healthy individuals. The results revealed no clinically significant impairment of psychomotor, cognitive, or complex behavior performance. However, since any psychoactive drug may impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that venlafaxine therapy does not adversely affect their ability to engage in such activities.

20 Reference ID: 3537473 Concomitant Medication Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, including herbal preparations and nutritional supplements, since there is a potential for interactions.

Patients should be cautioned about the risk of serotonin syndrome with the concomitant use of Effexor XR and triptans, tramadol, tryptophan supplements or other serotonergic agents (see CONTRAINDICATIONS and WARNINGS, Serotonin Syndrome and PRECAUTIONS, Drug Interactions, CNS-Active Drugs, Serotonergic Drugs).

Patients should be advised that taking Effexor XR can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle closure glaucoma. Pre-existing glaucoma is almost always open-angle glaucoma because angle closure glaucoma, when diagnosed, can be treated definitively with iridectomy. Open-angle glaucoma is not a risk factor for angle closure glaucoma. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.

Patients should be cautioned about the concomitant use of Effexor XR and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of bleeding (see PRECAUTIONS, Abnormal Bleeding).

–  –  –

Although venlafaxine has not been shown to increase the impairment of mental and motor skills caused by alcohol, patients should be advised to avoid alcohol while taking venlafaxine.

–  –  –

Drug Interactions As with all drugs, the potential for interaction by a variety of mechanisms is a possibility.

Alcohol A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects. Additionally, administration of venlafaxine in a stable regimen did not exaggerate 21 Reference ID: 3537473 the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.

Cimetidine Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects. The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%. However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine. The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly, and no dosage adjustment should be necessary for most normal adults. However, for patients with pre-existing hypertension, and for elderly patients or patients with hepatic dysfunction, the interaction associated with the concomitant use of venlafaxine and cimetidine is not known and potentially could be more pronounced. Therefore, caution is advised with such patients.

Diazepam Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.

Haloperidol Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC. In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged. The mechanism explaining this finding is unknown.





Lithium The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects. ODV also was unaffected. Venlafaxine had no effect on the pharmacokinetics of lithium (see also CNS-Active Drugs, below).

Drugs Highly Bound to Plasma Proteins Venlafaxine is not highly bound to plasma proteins; therefore, administration of Effexor XR to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.

Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have 22 Reference ID: 3537473 been reported when SSRIs and SNRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when Effexor XR is initiated or discontinued.

Drugs that Inhibit Cytochrome P450 Isoenzymes CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants. Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. CYP2D6 inhibitors such as quinidine would be expected to do this, but the effect would be similar to what is seen in patients who are genetically CYP2D6 poor metabolizers (see Metabolism and Excretion under CLINICAL PHARMACOLOGY). Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.

Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n = 14) and 25 mg in poor metabolizers (PM;

n = 6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.

Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.

Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PMs -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PMs

-38% to 105%) subjects, respectively. Combined AUCs of venlafaxine and ODV increased on average by approximately 23% in EMs and 53% in PMs (range in PMs 4% to 134%).

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. Therefore, caution is advised if a patient's therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.

Drugs Metabolized by Cytochrome P450 Isoenzymes CYP2D6: In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.

These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine with that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan.

Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine. The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h). Imipramine did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of elevated 2-OH-desipramine levels is unknown.

Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by 23 Reference ID: 3537473 approximately 30-40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.

Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study.

The clinical relevance of this finding for hypertensive patients is unknown. Caution should be exercised with co-administration of venlafaxine and metoprolol.

Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients. It is recommended that patients receiving Effexor XR have regular monitoring of blood pressure (see WARNINGS).

Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).

CYP3A4: Venlafaxine did not inhibit CYP3A4 in vitro. This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.

Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of this finding is unknown.

CYP1A2: Venlafaxine did not inhibit CYP1A2 in vitro. This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.

CYP2C9: Venlafaxine did not inhibit CYP2C9 in vitro. In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.

CYP2C19: Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).

–  –  –

See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.

CNS-Active Drugs The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above).

Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required. (See CONTRAINDICATIONS and WARNINGS, Serotonin Syndrome) 24 Reference ID: 3537473 Serotonergic Drugs: See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.

Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan. If concomitant treatment of Effexor XR with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS, Serotonin Syndrome).

–  –  –

False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking venlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine.

–  –  –

There are no clinical data establishing the benefit of electroconvulsive therapy combined with Effexor XR (venlafaxine hydrochloride) extended-release capsules treatment.

Postmarketing Spontaneous Drug Interaction Reports See ADVERSE REACTIONS, Postmarketing Reports.



Pages:     | 1 |   ...   | 3 | 4 || 6 | 7 |   ...   | 9 |


Similar works:

«DISSERTATION Titel der Dissertation Ethics in Mind Ethiopian Journalism and Ethics Verfasser: Worke Hailemarkos Ayalew Angestrebter akademischer Titel Doktor der Philosophie (Dr. phil) Wien, im 2011 Studienkennzahl lt. Studienblatt: A 092 301 Matrikelnummer: a0749672 Dissertationsgebiet lt. Studienblatt: Publizistikund Kommunikationswissenschaften Betreuer; Univ.-Prof. Dr. Thomas A. Bauer II To Fiori (Eminet Hailemarkos Ayalew), my cute Daughter For all the joy with which you fill my life. III...»

«Armoedeaanpak Gemeente Leeuwarden De kunst van het rondkomen Voorwoord Armoede is een onrecht. Het terugdringen van armoede is een belangrijke ambitie van dit college. Een ambitie die vele domeinen en dus portefeuilles raakt. Diverse portefeuillehouders werken aan integraal beleid voor armoedebestrijding. Daarnaast betrekken we de komende jaren nieuwe organisaties bij onze armoedeaanpak. Dat is een belangrijk speerpunt voor de komende jaren. De keuzes die we voorstellen zorgen er voor dat we...»

«The Hand-drill By Alan Halcon Introduction Growing up, I had a fascination with the outdoors. Every summer my dad would take us camping. After each trip, I would find myself preparing for the next trip by reading anything that I could on camping and outdoor survival. I remember hopping on my bike, riding to the local library, and sitting there for hours just looking through all the books on camping. I would constantly beg my mom to take me to the local sporting goods store in order to check out...»

«1 Pierrette Meisch, criminologue, Baptiste Antoine, licencié en licenciée en santé publique, formée sciences psychologiques, formé en en approche familiale systémique et médiation, Centre de Consultation et en médiation, directrice à la de Médiation Familiale de la Fondation Pro Familia Fondation Pro Familia Fondation Pro Familia A la recherche des significations des violences en milieu scolaire touchant les enfants « souffre-douleur » Abstract. L’article propose une réflexion...»

«AMBIGUOUS BORDERS: THE EUROPEAN COMMISSION AND THE RECONSTRUCTION OF BORDERS by VALENTINA KOSTADINOVA A thesis submitted to the Department of Political Science and International Studies of the University of Birmingham for the degree of Doctor of Philosophy in International Studies The University of Birmingham May 2010 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property...»

«Seeing Your First Child with PANDAS/PANS Margo Thienemann, MD and The PANDAS Physicians Network Diagnostics and Therapeutics Committee Seeing Your First Child with PANDAS/PANS I. What Is PANS? The term Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) describes the clinical presentation of a subset of pediatric onset Obsessive-Compulsive Disorder (OCD). PANS may also be a subset of Avoidant/Restrictive Food Intake Disorder (ARFID). While the criteria for diagnosing PANS do not specify a...»

«EDMUND GOSSE’S FATHER AND SON: RENEGOTIATING BIOGRAPHY THROUGH ILLUSTRATION KATHY REES Edmund Gosse (1849–1928) is known today for one classic text, Father and Son (1907), the account of his early life from 1849 to 1870 in his Plymouth Brethren home. It is a profile of mid-Victorian dissenter religion, where the recollections of the urbane narrator are periodically animated by the voice of the precocious but fragile child-focaliser. On publication the book was applauded for its...»

«Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits (PIP Framework) Questions and Answers September 2011 Contents: Page I. General 3 II. Advisory Group 4 III. Global Influenza Surveillance & Response System (GISRS) 6 IV. Pandemic Influenza Benefit Sharing 7 V. Partnership Contribution 7 VI. Standard Material Transfer Agreements 8 VII. Intellectual Property Rights 9 VIII. Influenza Virus Traceability Mechanism (IVTM) 10 This...»

«• HIGHLIGHTS OF PRESCRIBING INFORMATION Behavioral and mood disturbances: May Include euphoria, insomnia, mood These highlights do not include all the information needed to use Flo-Pred swings, personality changes, severe depression, and psychosis. Existing safely and effectively. See full prescribing information for Flo-Pred. conditions may be aggravated. (5.5) • Decreases in bone density: Monitor bone density in patients receiving longFlo-Pred (prednisolone acetate) Suspension for Oral...»

«STRAIGHTENING OUR HAIR bell hooks On Saturday mornings we would gather in the kitchen to get our hair fixed, that is straightened. Smells of burning grease and hair, mingled with the scent of our freshly washed bodies, with collard greens cooking on the stove, with fried fish. We did not go to the hairdresser. Mama fixed our hair. Six daughters—there was no way we could have afforded hairdressers. In those days, this process of straightening black women’s hair with a hot comb (invented by...»

«SPATIAL MEMORY RECALL IN THE GIANT PANDA (AILUROPODA MELANOLEUCA) A Thesis Presented to The Academic Faculty By Bonnie M. Perdue In Partial Fulfillment Of the Requirements for the Degree Masters of Science in Psychology Georgia Institute of Technology August, 2008 SPATIAL MEMORY RECALL IN THE GIANT PANDA (AILUROPODA MELANOLEUCA) Approved By: Dr. Terry L. Maple, Advisor School of Psychology Georgia Institute of Technology Dr. M. Jackson Marr School of Psychology Georgia Institute of Technology...»

«REWARD AND PUNISHMENT PROCESSING IN SUBGROUPS OF YOUTH WITH CONDUCT PROBLEMS: CHARACTERIZATION OF THE NEURAL RESPONSE AND IMPLICATIONS FOR INTERVENTION by Amy Lynn Byrd, Ph.D. B.S. in Psychology, College of Charleston, 2006 M.S. in Clinical Psychology, University of Pittsburgh, 2010 Submitted to the Graduate Faculty of The Kenneth P. Dietrich School of Arts and Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2015 UNIVERSITY OF...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.